glp 3 vs retatrutide Semaglutide and Tirzepatide: GLP-3 Facts explained π₯ Your Guide to the
Description
F., and Lean, M
How Does It Words
Efpeglenatide: The AMPLITUDE-O trial (2021) demonstrated a 27% MACE reduction (HR 0.73, 95% CI 0.580.92) in 4076 T2DM patients, with significant reductions in stroke and HF events [19]
Now access to those medications is anything but certain.
It is a Schedule II Controlled Substance in the United States, meaning it has a high potential for abuse and addiction
